Neuro-oncology, a decade of temozolomide and beyond.

  title={Neuro-oncology, a decade of temozolomide and beyond.},
  author={Roger Stupp and Monika E Hegi and Michael Weller},
  journal={Expert review of anticancer therapy},
  volume={10 11},
It has been a decade since the regulatory approval of temozolomide, the first drug specifically developed for the treatment of malignant glioma. Initially, only a conditional approval was granted by the US FDA based on a high radiological response rate in recurrent anaplastic astrocytoma, while in glioblastoma the observed responses in two pivotal studies were only 5 and 8%, respectively [1–3]. Nevertheless, the clinical observation that disease stabilization may be clinically relevant in this… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 11 extracted citations


Publications referenced by this paper.
Showing 1-10 of 16 references

Should wholebrain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma ? The GPCNSLSG 1 randomized Phase IV trial

  • E Thiel, A Korfel, P Martus
  • J . Clin . Oncol .
  • 2010

Similar Papers

Loading similar papers…